These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 11261810)
1. Anti-inflammatory therapy for Alzheimer's disease: implications of the prednisone trial. Aisen PS Acta Neurol Scand Suppl; 2000; 176():85-9. PubMed ID: 11261810 [TBL] [Abstract][Full Text] [Related]
2. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ; JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912 [TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Aisen PS; Davis KL; Berg JD; Schafer K; Campbell K; Thomas RG; Weiner MF; Farlow MR; Sano M; Grundman M; Thal LJ Neurology; 2000 Feb; 54(3):588-93. PubMed ID: 10680787 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of selective COX-2 inhibitors for the treatment of Alzheimer's disease. Aisen PS J Pain Symptom Manage; 2002 Apr; 23(4 Suppl):S35-40. PubMed ID: 11992749 [TBL] [Abstract][Full Text] [Related]
5. Non-steroidal anti-inflammatory drugs and cyclooxygenase in Alzheimer's disease. Hoozemans JJ; Veerhuis R; Rozemuller AJ; Eikelenboom P Curr Drug Targets; 2003 Aug; 4(6):461-8. PubMed ID: 12866660 [TBL] [Abstract][Full Text] [Related]
6. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease. Jaturapatporn D; Isaac MG; McCleery J; Tabet N Cochrane Database Syst Rev; 2012 Feb; (2):CD006378. PubMed ID: 22336816 [TBL] [Abstract][Full Text] [Related]
7. Cyclooxygenase and inflammation in Alzheimer's disease: experimental approaches and clinical interventions. Pasinetti GM J Neurosci Res; 1998 Oct; 54(1):1-6. PubMed ID: 9778144 [TBL] [Abstract][Full Text] [Related]
9. Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Reines SA; Block GA; Morris JC; Liu G; Nessly ML; Lines CR; Norman BA; Baranak CC; Neurology; 2004 Jan; 62(1):66-71. PubMed ID: 14718699 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA; Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517 [TBL] [Abstract][Full Text] [Related]
11. Neuroinflammation in Alzheimer's disease: potential targets for disease-modifying drugs. Hüll M; Hampel H Ernst Schering Res Found Workshop; 2002; (39):159-78. PubMed ID: 12066411 [No Abstract] [Full Text] [Related]
12. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Giovannini MG; Scali C; Prosperi C; Bellucci A; Pepeu G; Casamenti F Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):31-40. PubMed ID: 14552702 [TBL] [Abstract][Full Text] [Related]
13. Alzheimer's disease and inflammation: a review of cellular and therapeutic mechanisms. Halliday G; Robinson SR; Shepherd C; Kril J Clin Exp Pharmacol Physiol; 2000; 27(1-2):1-8. PubMed ID: 10696521 [TBL] [Abstract][Full Text] [Related]